Evidence map›Paper›PMID 20837122›Full record

ArticleInternational journal of pharmaceutics2010

Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.

Anekant Jain, Weili Yan, Keith R Miller, Ronan O'Carra, Jerold G Woodward, Russell J Mumper

Open access · greenAbstract read
In one paragraph

Article in International journal of pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Anekant JainDivision of Molecular Pharmaceutics, and the Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, United States.
Weili Yan
Keith R Miller
Ronan O'Carra
Jerold G Woodward
Russell J Mumper
University of North Carolina at Chapel Hill · USUniversity of Kentucky · USAuburn University · US

Funding

Nanoparticle HIV Protein Vaccines for Cellular ResponsesR01AI058842 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MUMPER, RUSSELL J · 2005 to 2009
$1.5M
Nanoengineered HIV-1 Vaccines Based on TatR21AI051147 · NIAID · UNIVERSITY OF KENTUCKY · PI MUMPER, RUSSELL J · 2003 to 2004
$412k
NIAID NIH HHS AI058842NIAID NIH HHS R01 AI058842NIAID NIH HHS R21 AI051147
6 · The paper itself

Abstract

The present studies were aimed at investigating the engineering of NPs with protein-conjugated-surfactant at their surface. In order to increase the immunogenicity of a protein antigen, Brij 78 was functionalized by tresyl chloride and then further reacted with the primary amine of the model proteins ovalbumin (OVA) or horseradish peroxide (HRP). The reaction yielded Brij 78-OVA and Brij 78-HRP conjugates which were then used directly to form NP-OVA or NP-HRP using a one-step warm oil-in-water microemulsion precursor method with emulsifying wax as the oil phase, and Brij 78 and the Brij 78-OVA or Brij 78-HRP conjugate as surfactants. Similarly, Brij 700 was conjugated to HIV p24 antigen to yield Brij 700-p24 conjugate. The utility of these NPs for enhancing the immune responses to protein-based vaccines was evaluated in vivo using ovalbumin (OVA) as model protein and p24 as a relevant HIV antigen. In separate in vivo studies, female BALB/c mice were immunized by subcutaneous (s.c.) injection with NP-OVA and NP-p24 formulations along with several control formulations. These results suggested that with multiple antigens, covalent attachment of the antigen to the NP significantly enhanced antigen-specific immune responses. This facile covalent conjugation and incorporation method may be utilized to further incorporate other protein antigens, even multiple antigens, into an enhanced vaccine delivery system.

Indexed as

Adjuvants, ImmunologicNanoparticlesAnimalsAntibody FormationDrug Delivery SystemsFemaleHIV Core Protein p24LipidsMiceMice, Inbred BALB COvalbuminPolyethylene GlycolsProteinsSulfonesVaccines2,2,2-trifluoroethanesulfonyl chlorideAdjuvants, ImmunologicHIV Core Protein p24Lipidsoctadecyl polyoxyethylene etherOvalbuminPolyethylene GlycolsProteinsSulfonesVaccines

Identifiers

PMID20837122
PMCPMC2967624
OpenAlexW2000741942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.